Current Report Filing (8-k)
September 18 2017 - 9:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 16, 2017
PIERIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Nevada
|
|
001-37471
|
|
EIN
30-0784346
|
(State of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
255 State Street, 9th Floor
Boston, MA
United States
(Address of principal executive offices, including zip code)
Registrants telephone number, including area code:
857-246-8998
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule
12b-2
of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
Emerging Growth Company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01
|
Regulation FD Disclosure.
|
On September 16, 2017, Pieris Pharmaceuticals, Inc. presented on the
safety, tolerability and pharmacodynamics of
PRS-080.
The poster is furnished as Exhibit 99.1 to this Current Report on Form
8-K
and is incorporated by reference herein.
The information set forth under this Item 7.01. Regulation FD Disclosure, including the exhibits attached hereto, shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set
forth by specific reference in such filing.
Item 9.01
|
Financial Statements and Exhibits
|
(d)
Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Dated: September 18, 2017
|
|
|
|
PIERIS PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Allan Reine
|
|
|
|
|
Name:
|
|
Allan Reine
|
|
|
|
|
Title:
|
|
Chief Financial Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Conference Poster of Pieris Pharmaceuticals, Inc., dated September 2017.
|
Pieris Pharmaceuticals (NASDAQ:PIRS)
Historical Stock Chart
From Apr 2024 to May 2024
Pieris Pharmaceuticals (NASDAQ:PIRS)
Historical Stock Chart
From May 2023 to May 2024